Efficacy and Safety of Benvitimod in Patients With Palmoplantar Pustulosis: An Open‐Label, Multicenter, Prospective Study.

Palmoplantar pustulosis (PPP) is often considered as pustular psoriasis of extremities. Benvitimod has been approved for mild to moderate psoriasis. We thus designed this study to evaluate the efficacy and safety of benvitimod for treating PPP. Of 47 PPP patients recruited from 4 hospitals, 40 finished 8 weeks visit and completed 4 weeks safety follow‐up visit. The Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI) and Dermatology Life Quality Index (DLQI) scores fell continuously. At week 8, mean ± SD PPPASI and DLQI were 3.39 ± 3.86 (p < 0.0001) and 2.49 ± 3.34 (p < 0.0001), respectively. At week 8, 70% (28/40) achieved PPPASI‐50 response, 35% (14/40) achieved PPPASI‐75 response, and 17.5% (7/40) achieved PPPASI‐90 response. Relapse occurred in 7.5% (3/40) of the patients. Of 47 patients enrolled, self‐reported compliance was 12.77% (6/47). Common drug‐related adverse events (5/47) included xerosis cutis. Only one patient's disease progressed during treatment. Our study demonstrated the efficacy and safety of benvitimod. [ABSTRACT FROM AUTHOR]